AstraZeneca plc vs Thomson Reuters Corp — how do they compare? AstraZeneca plc trades at $158.09 (market cap $248.14B), while Thomson Reuters Corp trades at $104.52 (market cap $45.38B). The key difference: AstraZeneca plc is far larger — about 5.5× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.5%). Which is the better fit depends on your goals.
| AZN | TRI | |
|---|---|---|
Market Cap | $248.14B | $45.38B |
Sector | Health | Industrials |
52-Week High | $209.48 | $178.77 |
52-Week Low | $147.06 | $76.55 |
Enterprise Value | $275.41B | $48.00B |
Dividend Yield | 2.01% | 2.5% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →